June 1, 2023 11:05 AM EDT
News Briefing

Bay­er buys li­cense to Cedil­la pre­clin­i­cal can­cer pro­gram; MEI Phar­ma says no to un­so­licit­ed of­fer

Lei Lei Wu

News Reporter

Paul Schloesser

Associate Editor

Bay­er has ac­quired ex­clu­sive rights to Cedil­la Ther­a­peu­tics’ pre­clin­i­cal can­cer drug can­di­dates for an undis­closed amount.

Bay­er an­nounced Thurs­day morn­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times